TABLE 2.

Summary of Recommendations

The American Cancer Society (ACS) endorses the Advisory Committee on Immunization Practices (ACIP) HPV vaccination recommendations, listed below, with one qualifying statement in bold italics Routine recommendations Routine HPV vaccination should be initiated at age 11 or 12 y. The vaccination series can be started beginning at age 9 y. Vaccination of females is recommended with 2vHPV, 4vHPV (as long as these formulations remain available), or 9vHPV. Vaccination of males is recommended with 4vHPV (as long as this formulation remains available) or 9vHPV. Recommendations for those not vaccinated at the routine age Vaccination is also recommended for females aged 13–26 y and for males aged 13–21 y who have not been vaccinated previously or who have not completed the 3-dose series. Males aged 22–26 y may be vaccinated.a ACS Qualifying Statement: Providers should inform individuals aged 22–26 y who have not been previously vaccinated or who have not completed the series that vaccination at older ages is less effective in lowering cancer risk. Special populations Vaccination is also recommended through age 26 y for men who have sex with men and for immunocompromised persons (including those with HIV infection) if not vaccinated previously.

2vHPV indicates bivalent human papillomavirus (HPV) vaccination; 4vHPV, quadrivalent HPV vaccination; 9vHPV, 9-valent HPV vaccination; HIV, human immunodeficiency virus.

^aACIP recommendation for individual clinical decision making.